Health ❯ Pharmaceuticals

Drug Regulation

FDA Quality Control Illegal Drug Trade FDA Approvals Mifepristone Public Health FDA Actions Active Pharmaceutical Ingredients Manufacturing Standards Vaccine Development Medicare Coverage Prescription Medications Agency Actions Counterfeit Drugs Tianeptine Covid-19 Treatments Market Access Product Recall Ivermectin Clinical Trials Approval Processes FDA Leadership Australia Tariffs Abortion Medications Narcotic Drugs Antidote Availability Counterfeit Medications Cannabis Products Safety and Efficacy Performance Enhancers Codeine Syrup Market Authorization Controlled Substances Government Actions European Medicines Agency Fixed Dose Combinations Compounding Over-the-Counter Medications Consumer Protection Ethics Health Policy Opioids

FDA Installs Tracy Beth Hoeg as Acting CDER Director as Pazdur Files Retirement

The acting appointment underscores internal rifts over rapid‑review plans that have unsettled stakeholders.

FDA Class II Recall Targets 580,000 Prazosin Bottles for Nitrosamine Overages

Ascend Recalls 141,984 Bottles of Generic Atorvastatin Over Dissolution Failures

FDA Flags Possible License Revocation for Sarepta’s Elevidys

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research

FDA Issues New Warning on Unapproved Tianeptine 'Gas Station Heroin' Products